Victory Capital Management Inc. Has $14.75 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Victory Capital Management Inc. cut its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 5.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 223,555 shares of the medical research company's stock after selling 12,393 shares during the period. Victory Capital Management Inc.'s holdings in Edwards Lifesciences were worth $14,752,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. GSA Capital Partners LLP bought a new position in Edwards Lifesciences during the 3rd quarter worth $481,000. Entropy Technologies LP acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $2,069,000. Versor Investments LP raised its holdings in shares of Edwards Lifesciences by 102.5% during the third quarter. Versor Investments LP now owns 4,455 shares of the medical research company's stock valued at $294,000 after buying an additional 2,255 shares during the last quarter. Addison Advisors LLC grew its holdings in Edwards Lifesciences by 915.1% in the 3rd quarter. Addison Advisors LLC now owns 18,038 shares of the medical research company's stock worth $1,190,000 after buying an additional 16,261 shares in the last quarter. Finally, Patten & Patten Inc. TN increased its position in Edwards Lifesciences by 7.5% in the 3rd quarter. Patten & Patten Inc. TN now owns 164,904 shares of the medical research company's stock valued at $10,882,000 after acquiring an additional 11,512 shares during the period. Institutional investors own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company's stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,262,521.36. This represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the firm's stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company's stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,000 shares of company stock valued at $2,657,000 over the last three months. 1.27% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Robert W. Baird decreased their price target on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating for the company in a research note on Friday, October 25th. Wells Fargo & Company dropped their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating on the stock in a research report on Monday, September 9th. Bank of America cut shares of Edwards Lifesciences from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $105.00 to $75.00 in a report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft dropped their target price on Edwards Lifesciences from $103.00 to $85.00 and set a "buy" rating on the stock in a report on Thursday, July 25th. Finally, Stifel Nicolaus lowered their price target on Edwards Lifesciences from $85.00 to $70.00 and set a "hold" rating on the stock in a research report on Thursday, July 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $75.67.

Edwards Lifesciences Trading Down 1.7 %

NYSE EW traded down $1.20 on Wednesday, hitting $69.00. 216,638 shares of the stock were exchanged, compared to its average volume of 4,635,684. The company's 50-day moving average price is $67.59 and its two-hundred day moving average price is $75.91. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a market capitalization of $40.70 billion, a price-to-earnings ratio of 10.13, a P/E/G ratio of 3.81 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts' consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the previous year, the company posted $0.59 earnings per share. Edwards Lifesciences's revenue for the quarter was up 8.9% compared to the same quarter last year. Research analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.